GSK partners with Chinese biotech on coronavirus vaccine

A few weeks back, GlaxoSmithKline proclaimed it would offer up its adjuvant platforms to companies working on a coronavirus vaccine. Now China’s Clover Biopharmaceuticals is taking GSK up on that proposition — using the latter's compounds to help enhance the efficacy of its Covid-19 vaccine candidate. GSK, however, is not developing a coronavirus vaccine of its own.

Major vaccine players haven’t been as eager as drug developers to focus in on coronavirus, STAT’s Andrew Joseph writes. Smaller biotechs, in particular, are focusing on this new pathogen — but if they want any sort of scale, they’ll ultimately have to partner with a larger company, such as GSK.